Curaleaf Holdings (CURLF) Non Operating Income (2019 - 2026)
Curaleaf Holdings (CURLF) posted quarterly Non Operating Income of -$29.4 million for Q1 2026, down 14.03% year-on-year from -$34.2 million in Q1 2025, and down 8.61% on a QoQ basis from -$27.1 million in Q4 2025.
Curaleaf Holdings (CURLF) Non Operating Income (2019 - 2026) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Non Operating Income for 8 consecutive years, with -$29.4 million the latest figure, recorded in Q1 2026.
- Quarterly Non Operating Income fell 14.03% year-over-year to -$29.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$107.3 million (up 23.21% YoY) and the FY2025 annual result came in at -$103.7 million, up 24.94% from the prior year.
- Non Operating Income eased to -$29.4 million in Q1 2026 per CURLF's latest filing, from -$27.1 million in the prior quarter.
- Over the last five years, Non Operating Income for CURLF reached as high as -$3.2 million in Q2 2022 and fell as low as -$74.6 billion in Q4 2023.
- A 5-year average of -$4.4 billion and a median of -$24.7 million in 2024 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2023 — Non Operating Income sank 44383.47% — and 2024, when it jumped 99.91%.
- Year by year, Non Operating Income stood at -$167.7 million in 2022, then plunged by 44383.47% to -$74.6 billion in 2023, then soared by 99.91% to -$68.2 million in 2024, then soared by 60.35% to -$27.1 million in 2025, then slipped by 8.61% to -$29.4 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered -$29.4 million, -$27.1 million, and -$28.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -216.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 20.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -7.50 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 53.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | -29.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.38 Mn |
| Dec 31, 2025 | -27.05 Mn |
| Sep 30, 2025 | -28.34 Mn |
| Jun 30, 2025 | -22.51 Mn |
| Mar 31, 2025 | -25.77 Mn |
| Dec 31, 2024 | -68.23 Mn |
| Sep 30, 2024 | -21.01 Mn |
| Jun 30, 2024 | -24.71 Mn |
| Mar 31, 2024 | -24.19 Mn |
| Dec 31, 2023 | -74.59 Bn |
| Sep 30, 2023 | -51.17 Mn |
| Jun 30, 2023 | -20.36 Mn |
| Mar 31, 2023 | -21.13 Mn |
| Dec 31, 2022 | -167.69 Mn |
| Sep 30, 2022 | -23.97 Mn |
| Jun 30, 2022 | -3.20 Mn |
| Mar 31, 2022 | -22.35 Mn |
| Dec 31, 2021 | -50.86 Mn |
| Sep 30, 2021 | -38.96 Mn |
| Jun 30, 2021 | -19.03 Mn |